Research programme: insulin oral - Abeona Therapeutics

Drug Profile

Research programme: insulin oral - Abeona Therapeutics

Alternative Names: cobalamin-coated insulin-containing nanoparticles; CobOral™ Insulin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Access Pharmaceuticals
  • Developer Abeona Therapeutics
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
  • 10 Feb 2014 This programme is still in preclinical development in USA
  • 10 Feb 2014 Research programme: insulin oral - Access Pharmaceuticals is available for licensing as of 20 Mar 2013. http://www.accesspharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top